Neuren Pharmaceuticals (ASX:NEU) Records 594% Jump in 1HFY24 Royalty Revenue, Expects Continued Growth in FY24
Neuren Pharmaceuticals Limited (ASX:NEU), an ASX-listed biopharmaceutical company focused on neurological disorder treatments, has reported significant financial and regulatory developments. Recently, the company has experienced substantial growth in royalty revenue, strengthened its partnership with Acadia Pharmaceuticals, and is advancing clinical trials for NNZ-2591.
Team Kalkine |
12 Feb 2025| Read Time : 10 Mins